UPDATE - Canaccord Genuity Initiates Coverage on Anthera Pharma (ANTH) at Buy; Two Shots on Phase 3 Goal
Tweet Send to a FriendGet Alerts ANTH Hot Sheet
Price: $0.61 +5.17%
Rating Summary:
7 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
7 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ANTH Now!
UPDATE - Canaccord Genuity initiates coverage on Anthera Pharma (NASDAQ: ANTH) with a Buy rating and $13 price target.
Canaccord analyst, Ritu Baral, said, "Initiating with BUY, $13 target on good chance of blisibimod Phase 2/3 lupus success and positive Phase 3 varespladib ACS data in 2012. Blisibimod is Anthera’s Phase 2/3 BAFF peptibody for lupus, which we think will yield positive data from the ongoing PEARL-SC trial in Q2/12. We also think sPLA2 inhibitor varespladib will show clinically meaningful benefit in post-ACS cardiovascular risk in mid-2012, from the ongoing VISTA-16 trial."
"We believe either blisibimod or varespladib could be the basis of a rich partnership. We also see Anthera as an attractive takeout candidate in the 2013 timeframe."
To see more ratings on ANTH, Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Canaccord analyst, Ritu Baral, said, "Initiating with BUY, $13 target on good chance of blisibimod Phase 2/3 lupus success and positive Phase 3 varespladib ACS data in 2012. Blisibimod is Anthera’s Phase 2/3 BAFF peptibody for lupus, which we think will yield positive data from the ongoing PEARL-SC trial in Q2/12. We also think sPLA2 inhibitor varespladib will show clinically meaningful benefit in post-ACS cardiovascular risk in mid-2012, from the ongoing VISTA-16 trial."
"We believe either blisibimod or varespladib could be the basis of a rich partnership. We also see Anthera as an attractive takeout candidate in the 2013 timeframe."
To see more ratings on ANTH, Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Needham & Company Starts Infoblox (BLOX) at Buy; Margin Expansion Story
- Barclays Starts SBA Communications (SBAC) at Overweight
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
